Global Education Ltd. Share Price

Tech Mahindra Ltd. SURGE 7% AFTER STRONG Q2

Tech M provides IT consulting, digital transformation

INDIAN MARKETS WEEKLY UPDATE | BULLS MAKE A STRONG COMEBACK!

Indian equity markets delivered their strongest weekly performance in nearly 6 months during the week ended 16 October 2026; with the Nifty 50 gaining approximately 2.8% and the Sensex rising around 3.1%. After facing sustained selling pressure and global uncertainty, the market witnessed a powerful recovery, led by renewed buying in heavyweight stocks. IT SECTOR EMERGES AS THE BIGGEST OUTPERFORMER The star performer was undoubtedly the IT sector. The Nifty IT index surged approximately 11.7% for the week, marking its strongest weekly gain in around 18 years. Better-than-expected quarterly earnings and improved commentary on AI-driven business opportunities helped revive investor confidence. Stocks such as TCS, Infosys, HCLTech and Tech Mahindra attracted strong buying interest, contributing significantly to the broader market recovery.

Hindalco : Can Metal Stocks Sustain Their Momentum?

Mankind Pharma enters CAR-T therapy with €48 million deal

Mankind Pharma Limited (NSE: MANKIND) has agreed to acquire a 70% stake in Belgium-based Armed Cell Therapeutics B.V. for €48 million through its Netherlands subsidiary. The deal marks Mankind Pharma’s entry into next-generation CAR-T cancer therapies. Mankind Pharma Key details • Acquisition stake: 70%. • Investment: €48 million, to be paid in cash. • Armed Cell Therapeutics is developing next-generation CAR-T therapies for cancer. • Its lead programmes target non-Hodgkin lymphoma and small cell lung cancer. • The company is also working on approaches such as in-vivo CAR-T generation. My view The deal is strategically important because it moves Mankind beyond its traditional domestic formulations and consumer-healthcare base into a much more research-intensive therapy segment. But this is also an early-stage biotech investment. The value will depend on clinical progress, regulatory approvals and whether these therapies ultimately reach commercialisation. So the €48 million investment should be viewed as a long-term innovation bet rather than an immediate earnings driver. What I’m watching next I will watch clinical-development milestones for the lead CAR-T programmes, regulatory progress and whether Mankind makes further investments in global specialty therapies. Stance: Strategically positive, but the financial payoff depends on successful clinical development and commercialisation. Disclosure: I do not have any holding or position in the stock mentioned above.

Daily Index View : NIFTY50 as on 16/10/2026

1. Market Trend PROBABILITY 🚨 Current Market Trend: Positive 🚀 20% 🔍 Key Level to Watch: 22582 🔄 Current Market Surface: The trend will stay Positive until the market stay above 22582 That’s 416 points away from the last day Closing Price of 22997 ATR 345 2. Demand & Supply PROBABILITY Force is Demand & Supply is Modarate 10% Last 3 days market has rallied, but not too much compared to ATR, so demand has good firepower 15 Oct 2026 FII Cash-net (Buy/sell) DII Cash- net (BUY/SELL) -5,285 +3,319.39 3. Reflexivity PROBABILITY First Half is Supportive to Bullish Momentum for at least first half 10% Last day market rallied Intraday more than the 8-day average ATR, so it should keep its momentum intact in the first half 4. Social Proof (Global) PROBABILITY Dow Jones (Last day close) 48185 Up/Donw by 52,178 #DIV/0! Dow jones future (live) 52,474 Up/Donw by +44.0 Hang seng (Live) 24063 Up/Donw by 124 Nikki 225 (Live) 65324 Up/Donw by 898 Sentiments: Dow Jones Futures is Trading Flat to Positive & HANG SENG Index is trading Flat to Positive Today, global markets are neutral to slightly positive, and the Indian market has no strong directional bias